Barriers and facilitators for adherence to antiretroviral therapy in Papua New Guinea

Current HIV Research

Volumn 8, Issue 8, 2010, Pages 630-637

  Kelly, A ^a,b   Worth, H ^b   Man, N ^b   Nosi, S ^a   Emori, R ^a   Mek, A ^a   Akuani, F ^a   Kupul, M ^a   Kepa, B ^a   Walizopa, L ^a   Pirpir, L ^a   Cangah, B ^a   Siba, P ^a   Frankland, A ^c   Rawstorne, P ^b  

^a PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adherence; AIDS; Antiretroviral therapy (ART); HIV; Papua New Guinea; Resource poor settings

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HEALTH CENTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; PAPUA NEW GUINEA; PATIENT COMPLIANCE; PRIVATE HOSPITAL; RELIGION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; PAPUA NEW GUINEA; PATIENT COMPLIANCE; SOCIOECONOMIC FACTORS;

EID: 78650882216     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210794088191     Document Type: Article

References (37)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338(13): 853-60.
2. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDS 2001; 15(4): 185-91.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133(1): 21-30.
4. Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34(8): 1115-21.
5. Altice F, Friedland G. The era of adherence to antiretroviral therapy. Ann Intern Med 1998; 129(6): 503-5.
6. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000; 12(4): 377-86.
7. Race K, Wakeford E. Dosing on time: Developing adherent practice with highly active anti-retrovral therapy. Cult Health Sex 2000; 2(2): 213-28.
8. Edwards LV. Perceived social support and HIV/AIDS medication adherence among African American Women. Qual Health Res 2006; 16(5): 679-91.
9. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999 Sep 10; 13(13): 1763-9.
10. Murphy DA, Marelich WD, Hoffman D, et al. Predictors of antiretroviral adherence. AIDS Care 2004; 16(4): 471-84.
11. Remien RH, Hirky AE, Johnson MO, et al. Adherence to medication treatment: a qualitative study of facilitators and barriers among a diverse sample of HIV+ men and women in four US cities. AIDS Behav 2003; 7(1): 61-72.
12. Diiorio C, McCarty F, Depadilla L, et al. Adherence to antiretroviral medication regimens: a test of a psychosocial model. AIDS Behav 2009; 13(1): 10-22.
13. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, et al. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005; 16(1): 38-41.
14. Pinheiro CA, de-Carvalho-Leite JC, Drachler ML, et al. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. Braz J Med Biol Res 2002; 35(10): 1173-81.
15. Stout BD, Leon MP, Niccolai LM. Nonadherence to antiretroviral therapy in HIV-positive patients in Costa Rica. AIDS Patient Care STDS 2004; 18(5): 297-304.
16. Wang H, He G, Li X, et al. Self-Reported adherence to antiretroviral treatment among HIV-infected people in Central China. AIDS Patient Care STDS 2008; 22(1): 71-80.
17. Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000; 19(2): 124-33.
18. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care 2000; 12(3): 255-66.
19. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(2): 117-25.
20. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2001; 26(1): 82-92.
21. Weidle PJ, Ganera CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr 1999; 22(5): 498-502.
22. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther 2002; 7(3): 185-93.
23. Aronson JK. Adherence, concordance, adherence. Br J Clin Pharmacol 2007; 63(4): 383-84.
24. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296(6): 679-90.
25. Sherr L, Lampe F, Norwood S, et al. Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care 2008; 20(4): 442-8.
26. Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS 2004; 15(1): 38-44.
27. Sankar AP, Nevedal DC, Neufeld S,. What is a missed dose? Implications for construct validity and patient adherence. AIDS Care 2007; 19(6): 775-80.
28. Liu H, Miller LG, Golin CE, et al. Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Stat Med 2007; 26(5): 991-1007.
29. Herman S, McKinnon E, John M, et al. Side effects, dosing schedules, pill burden and perceived stress: interaction and influence on medication adherence. Presented at: 20th Annual ASHM Conference. Perth, Australia, 2008.
30. Cauldbeck M, O'Connor C, Saunders J, et al. Adherence to antiretroviral therapy among patients in Bangalore, India. Presented at: 20th Annual ASHM Conference. Perth, Australia, 2008.
31. Hardon AP, Davey S, Gerrits T, et al. From access to adherence: The challenges of antiretroviral treatment Studies from Botswana, Tanzania and Uganda, 2006. Geneva, Switzerland: World Health Organizat; 2006.
32. Kelly A. "The body of Christ Has AIDS": the Catholic Church responding faithfully to HIV and AIDS in Papua New Guinea. J Relig Health 2009; 48: 16-28.
33. Hammar L. Fear and Loathing in Papua New Guinea: sexual behaviour and sexual health in a nation under siege. In: Butt L, Eves R, Eds. Making Sense of AIDS: culture, sexuality, and power in Melanesia. Honolulu: University of Hawaii Press 2008; pp. 60-79.
34. Brigido L, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-infected patients at a university public service in Brazil. AIDS Patient Care STDS 2001; 15(11): 587-93.
35. Laurent C, Diakhate N, Gueye NF, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16(10): 1363-70.
36. Au JT, Kayitenkore K, Shutes E, et al. Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda. AIDS Care 2006; 20(16): 2116-8.
37. Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 2007; 19(5): 658-65.